肿瘤细胞治疗研究
英文原题：CD70-targeted CAR-T/NK therapy: Rationale, advances, and future directions.
CAR-T 细胞和自然杀伤（CAR-T/NK）细胞是一项快速发展的细胞免疫治疗技术，在血液系统疾病治疗中已取得巨大成就。
CAR-T 细胞和NK 细胞（CAR-T/NK）是一种快速发展的细胞免疫治疗技术，在血液系统疾病治疗中取得了显著进展。CD70是多种血液系统恶性肿瘤（包括急性髓系白血病、非霍奇金淋巴瘤和多发性骨髓瘤等）以及肾细胞癌、骨肉瘤和胶质瘤等实体瘤细胞表面表达的抗原，是CAR-T/NK细胞的潜在靶点。目前，针对CD70的CAR-T/NK临床前研究和临床试验正在开展，为治疗CD70阳性肿瘤带来新的希望。
Chimeric antigen receptor T and natural killer (CAR-T/NK) cells is a rapidly evolving cellular immunotherapy technology that has made great achievements in the treatment of hematologic diseases. CD70, as a surface antigen expressed on tumor cells in a variety of hematologic malignancies, including acute myeloid leukemia, non-Hodgkin lymphoma, multiple myeloma, etc., and solid tumors such as renal cell carcinoma, osteosarcoma, and glioma, is a potential target for CAR-T/NK cells. Several preclinical studies and clinical trials on CAR-T/NK cells targeting CD70 are currently underway, bringing new hope for the treatment of CD70-positive tumors.
MEMBER ACCOUNT
登录成功会直接打开下一页。
